<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00844779</url>
  </required_header>
  <id_info>
    <org_study_id>3966</org_study_id>
    <nct_id>NCT00844779</nct_id>
  </id_info>
  <brief_title>Molecular Investigation of Non Alcoholic Fatty Liver Diseases in Obese Patients</brief_title>
  <official_title>Evaluation of Non Alcoholic Metabolic Liver Diseases in Patients Harboring Central Adiposity and Insulin Resistance by Biochemical and Functional Genomic Approaches</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non alcoholic fatty liver diseases (NAFLD) are represented by two main pathological
      conditions, hepatic steatosis (HS) and non alcoholic steatohepatitis (NASH), which are
      characterized by the accumulation of fat in the liver. The diagnosis of these two entities is
      achieved by histology and neither imaging nor biochemical markers are accurate enough to
      discriminate them. At the contrary of HS, NASH features hepatocyte necrosis, inflammation and
      fibrosis of variable intensity that could progress and ultimately evolve to cirrhosis.
      Therefore, it is important to distinguish between HS and NASH in order to treat the patients
      accordingly. In this study, the investigators aim to understand the molecular mechanisms that
      govern the transition from benign steatosis to complicated NASH. The investigators will
      analyze by &quot;Q-RT-PCR&quot; and &quot;DNA microarray&quot; technologies in the liver of obese patients, the
      expression of genes that are susceptible to be involved in the pathogenesis of NAFLD and
      identify the potential signaling pathways responsible for the progression of the disease.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2009</start_date>
  <completion_date type="Anticipated">January 2011</completion_date>
  <primary_completion_date type="Anticipated">January 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Liver Disease</condition>
  <arm_group>
    <arm_group_label>T</arm_group_label>
    <description>(n=30): without central adiposity, without insulin resistance, operated for cholecystectomy or a benign liver tumor.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <description>(n=30): with central adiposity, insulin resistance and hepatic steatosis (histology).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <description>(n=30): with central adiposity, insulin resistance and steatohepatitis ± hepatic fibrosis (histology).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bariatric surgery</intervention_name>
    <description>Gastric bypass.</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>cholecystectomy or benign liver tumor removal</intervention_name>
    <description>cholecystectomy or benign liver tumor removal</description>
    <arm_group_label>T</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Primary care clinic
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Group T(n=30): patient without central adiposity, without insulin resistance, operated
             for cholecystectomy or a benign liver tumor

          -  Group A (n=30): patient with central adiposity, insulin resistance and hepatic
             steatosis (histology).

          -  Group B (n=30): patient with central adiposity, insulin resistance and steatohepatitis
             ± hepatic fibrosis (histology).

        Exclusion Criteria:

          -  viral or autoimmune hepatitis

          -  hematochromatosis

          -  alcohol consumption (&gt; 20 g/24h women, &gt;30 g/24h men)

          -  type 1 diabetes

          -  inflammation or infection before procedure

          -  abnormal hemostasis or coagulation- pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michel DOFFOEL, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hôpitaux Universitaires de Strasbourg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ahmed Nassim DALI YOUCEF, PHD</last_name>
    <phone>(33) 3.69.55.11.84</phone>
    <email>ahmed.nassim.dali.youcef@chru-strasbourg.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michel DOFFOEL, MD</last_name>
    <phone>(33) 3 69 55 04 82</phone>
    <email>michel.doffoel@chru-strasbourg.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Service d'Hépato-Gastro-Entérologie - Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel DOFFOEL, MD</last_name>
      <phone>(33) 3 69 55 04 82</phone>
      <email>michel.doffoel@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>François HABERSETZER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michel DOFFOEL, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive et Endocrinienne - Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michel VIX, MD</last_name>
      <phone>(33) 3 69 55 10 52</phone>
      <email>michel.vix@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Michel VIX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jacques MARESCAUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2009</study_first_submitted>
  <study_first_submitted_qc>February 13, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 16, 2009</study_first_posted>
  <last_update_submitted>April 24, 2009</last_update_submitted>
  <last_update_submitted_qc>April 24, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 27, 2009</last_update_posted>
  <responsible_party>
    <name_title>Christine GEILLER</name_title>
    <organization>Direction de la Recherche Clinique et de l'Innovation - Hôpitaux Universitaires de Strasbourg</organization>
  </responsible_party>
  <keyword>Metabolic syndrome- hepatic steatosis- steatohepatitis - gene expression</keyword>
  <keyword>Non alcoholic fatty liver disease (NFALD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Liver Extracts</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

